COVID-19 in Immunocompromised Hosts: What We Know So Far.

Area of Science:

• Immunology
• Infectious Diseases
• Oncology

Background:

• The COVID-19 pandemic has severely impacted global health systems.
• Understanding COVID-19 outcomes in immunocompromised individuals is crucial due to their presumed higher risk of severe disease.
• The interplay between immunosuppression, inflammation, and COVID-19 severity is not fully understood.

Purpose of the Study:

• To review and characterize the clinical features and outcomes of COVID-19 in various immunocompromised populations.
• To assess the specific risks associated with different types of immunosuppression on COVID-19 prognosis.

Main Methods:

• Systematic literature review of existing studies on COVID-19 in immunocompromised patients.
• Analysis of data from diverse immunocompromised groups including cancer patients, solid-organ transplant recipients, HIV patients, and those with autoimmune diseases on immunomodulatory therapy.

Main Results:

• Patients with malignancy and solid-organ transplant recipients appear to have an increased risk of severe COVID-19 and mortality.
• Evidence regarding COVID-19 severity and outcomes in other immunocompromised populations (e.g., HIV, autoimmune diseases) is less conclusive.
• The impact of specific immunomodulatory therapies on COVID-19 prognosis requires further investigation.

Conclusions:

• Certain immunocompromising conditions, notably malignancy and organ transplantation, are associated with poorer COVID-19 outcomes.
• Further prospective, controlled studies are essential to precisely define the attributable risk of various immunosuppressive conditions and treatments on COVID-19 prognosis.
• Clarifying these risks will aid in optimizing patient management and public health strategies during the pandemic.